Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals, and horses. The Company is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products. Its pipeline includes prescription drug product candidates for over eight indications across various species and non-prescription products targeting over seven species. Its product candidates include Canalevia, Species-specific formulations of crofelemer, Virend (topical), Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm. Canalevia is its lead prescription drug product candidate for the treatment of various forms of diarrhea in dogs. Neonorm is its lead non-prescription product to support gut health thereby normalizing fecal formation in animals suffering from watery diarrhea, or scours. Its Neonorm operates under Neonorm Calf and Neonorm Foal.
